ArticleEJNMMI radiopharmacy and chemistry2026
Automated and manual synthesis of [
Article in EJNMMI radiopharmacy and chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundFibroblast activation protein is a well-established target for tumour imaging, and single-domain antibodies (sdAb) offer favourable pharmacokinetic properties for PET applications. However, the translation of sdAb-based radiotracers into robust and clinically applicable manufacturing processes remains limited. Previously, preclinical protocol for the production of [
resultsEfficient radiolabelling was achieved at 50 °C for 10 min, with radiochemical conversion exceeding 90% and no need for purification. Both automated and manual processes showed consistent performance, with radiochemical purities of 99.5 ± 0.5% (n = 9) and 96.3 ± 1.5% (n = 8) as determined by iTLC and SE-HPLC respectively, with associated non-decay-corrected radiochemical yields of 78.3 ± 3.3% (n = 9) and 76.9 ± 2.1% (n = 8). The main source of activity loss was the radioactive decay of
conclusionA robust and reproducible manufacturing process for [
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.